Skip navigation

Get exclusive benefits after your first order:

-10 %

VICHY

VICHY NEOVADIOL PERI-MENOPAUSE ANTI-WRINKLE DAY CREAM FOR NORMAL/COMBINATION SKIN 50ML

Product from
Farmacia
1 pc
Until 01/01
RON 190.79  RON 211.99
RON 190.79 /pc

Delivery within 3 hours


You're reading an Auto-translation.

 

 

NEOVADIOL PERI-MENOPAUSE
REDENSIFYING AND REPLUMPING DAY CREAM - NORMAL TO COMBINATION SKIN

Neovadiol redensifying day cream improves elasticity, smoothes the skin and redefines contours.

Enriched with Proxylane, Cassia extract and Hyaluronic Acid, it helps to compensate for the impact of menopause by improving the appearance of the complexion: it appears denser, plumper and feels firmer.

The formula has been clinically tested by dermatologists on menopausal women with sensitive skin.

    Smoothes the skin and redefines contours. Improves elasticity.
    *MOISTURIZATION +40%
    **FIRMNESS +13%
    **ELASTICITY +22%
    *Instrumental test on 24 women after 4 hours
    **Instrumental test on 40 women after 4 hours

 

EXPOSOME SCIENCE

During perimenopause, hormonal variations accelerate the signs of skin aging, leading to loss of skin elasticity, density and facial contour definition.
 

 

 

 

SAFETY

Hypoallergenic formula. Tested under dermatological control on menopausal women with sensitive skin.
 

 

How to apply

Apply to the face and neck on previously cleansed skin, avoiding the eye area.
 

 

Menopause expertise

During perimenopause, hormonal variations affect the skin. Estrogen, the female hormone decreases while cortisol, the stress hormone increases. The combination of these variations affects the skin on 5 levels:

1. Collagen decreases. Wrinkles are deeper.
2. Hyaluronic acid production decreases. The skin loses its density and elasticity.
3. Antioxidant protection is impaired, signs of aging appear.
4. Cell renewal slows down. The skin loses its radiance.
5. Night sweats appear, causing a sensation of heat.
 

Routine:

 

 

 

*Study conducted on the dermocosmetic market by AplusA between January and March 2022, on a sample of 100 dermatologists from Romania.